Citigroup downgraded Hims & Hers Health (NYSE: HIMS) from 'Buy' to 'Neutral', raising price target from $16.00 to $20.00.
Citigroup downgraded Hims & Hers Health (NYSE: HIMS) from a 'Buy' to 'Neutral' rating, raising the price target from $16.00 to $20.00. The company reported $0.05 EPS, surpassing estimates by $0.03 and a 45.8% year-over-year revenue increase. Canaccord Genuity Group raised its price target to $24.00 with a 'Buy' rating, while Imperial Capital set a $16.00 target with an 'Outperform' rating.
May 26, 2024
3 Articles